{"hands_on_practices": [{"introduction": "The bedrock of an individual's control over their biological materials often rests on specific statutes designed to honor their wishes. The Uniform Anatomical Gift Act (UAGA) is a primary example, creating a legal framework that prioritizes the documented intent of a donor above all else. This practice problem challenges you to act as legal counsel for an organ procurement organization faced with conflicting documents, requiring you to apply the UAGA's rules of precedence to determine the donor's final, legally binding intent [@problem_id:4501844]. It is a fundamental exercise in statutory interpretation and highlights how the law gives effect to personal autonomy even after death.", "problem": "A decedent, Alex, executed a donor registration on a state driver’s license in $2018$, authorizing an anatomical gift of “organs and tissues for transplantation, therapy, research, or education.” In $2022$, Alex executed a written advance health care directive that included the clause, “I do not consent to post-mortem use of my body, organs, or tissues for research or education,” and signed and dated it in the presence of $2$ adult witnesses as required by state advance directive law. The advance directive made no mention of revoking transplantation or therapy uses. In $2024$, Alex died suddenly. Before recovery, the organ procurement organization obtained copies of both the $2018$ donor registration and the $2022$ advance directive.\n\nAssume the state has enacted the Uniform Anatomical Gift Act (UAGA) $2006$ revision without material alteration. Use only the following foundational premises: (i) under common law there is no ordinary property right in a human body, but statutory regimes such as the UAGA govern authorization and control by honoring donor intent; (ii) the UAGA permits a donor to make, amend, or revoke an anatomical gift by specified methods and prioritizes the donor’s documented intent over that of next of kin; and (iii) under the UAGA, a later valid amendment or refusal by the donor controls over earlier, inconsistent donor records, and delivery of the document is not required for validity, although persons who act without knowledge of an amendment are protected.\n\nApplying these premises to the conflict between the $2018$ donor registration and the $2022$ research restriction, which option best states the controlling instrument and the lawful scope of post-mortem use?\n\nA. The $2018$ driver’s license donor registration controls in full; the organ procurement organization may use Alex’s tissues for research, education, transplantation, and therapy because the earlier, broader authorization cannot be narrowed by a later advance directive.\n\nB. The $2022$ advance directive controls to the extent of its restriction; it validly amends the prior anatomical gift to bar research and education uses, while leaving transplantation and therapy uses authorized.\n\nC. Alex’s next of kin control because of the conflict; they may override both documents and decide whether to allow research or other uses.\n\nD. The conflict between the $2018$ and $2022$ documents voids both instruments; no anatomical gift is permitted for any purpose absent a court order.", "solution": "The problem statement will first be validated for logical consistency, scientific grounding, and completeness based on the provided text and premises.\n\n**Step 1: Extract Givens**\n-   **Decedent:** Alex\n-   **Document 1:** A $2018$ donor registration on a state driver’s license.\n    -   **Authorization:** Anatomical gift of “organs and tissues for transplantation, therapy, research, or education.”\n-   **Document 2:** A $2022$ written advance health care directive.\n    -   **Clause:** “I do not consent to post-mortem use of my body, organs, or tissues for research or education.”\n    -   **Execution:** Signed and dated in the presence of $2$ adult witnesses, compliant with state advance directive law.\n    -   **Scope:** The directive “made no mention of revoking transplantation or therapy uses.”\n-   **Event:** Alex died suddenly in $2024$.\n-   **State of Knowledge:** The organ procurement organization (OPO) possessed copies of both the $2018$ and $2022$ documents prior to organ recovery.\n-   **Governing Law:** The state has enacted the Uniform Anatomical Gift Act (UAGA) $2006$ revision without material alteration.\n-   **Foundational Premises:**\n    -   (i) Common law disavows property rights in a human body, but statutory law, like the UAGA, governs authorization by honoring donor intent.\n    -   (ii) The UAGA specifies methods for a donor to make, amend, or revoke an anatomical gift and prioritizes documented donor intent over the wishes of next of kin.\n    -   (iii) A later, valid amendment or refusal by the donor supersedes earlier, inconsistent donor records. Delivery of such a document is not required for its validity.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is presented as a logical puzzle requiring the application of a given set of legal axioms (premises) to a specific factual scenario.\n\n1.  **Scientific Grounding:** The problem is situated in medical law, a field that, while not a natural science, relies on rigorous logical deduction and interpretation of established principles. The premises provided are accurate, albeit simplified, representations of the legal principles within the Uniform Anatomical Gift Act ($2006$ revision). The problem is therefore grounded in the established logical framework of a specific legal doctrine. It is valid.\n2.  **Well-Posedness:** The problem is well-posed. It presents a clear conflict between two documents and provides explicit rules (premises) for resolving such a conflict. The question asks for a specific outcome—the controlling instrument and its scope—which can be uniquely determined by applying the premises to the facts. It is valid.\n3.  **Objectivity:** The problem is stated in precise, objective language. The facts are presented without bias, and the premises are stipulated as the sole basis for the analysis. It is valid.\n4.  **Flaw Analysis:**\n    -   The problem contains no scientific or logical contradictions. The conflict between the two documents is the central puzzle to be solved, not a flaw in the problem's construction.\n    -   The setup is self-contained and complete. All information necessary to apply the premises is provided.\n    -   The scenario is realistic and legally plausible.\n    -   The problem requires substantive logical reasoning to resolve the partial conflict between the two documents and is not trivial or tautological.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. The analysis may proceed.\n\n**Derivation of Solution**\n\nThe core of the problem is to resolve the conflict between Alex's $2018$ general anatomical gift and the $2022$ specific refusal. The provided premises will be applied systematically.\n\n1.  **Principle of Donor Intent:** Premise (i) and (ii) establish that the donor's intent is paramount. The UAGA's purpose is to honor that intent as documented. We have two documents of intent from the donor, Alex.\n\n2.  **Principle of Amendment/Revocation:** Premise (ii) explicitly states that a donor may \"amend, or revoke\" an anatomical gift. Premise (iii) provides the rule for resolving inconsistencies: \"a later valid amendment or refusal by the donor controls over earlier, inconsistent donor records.\"\n\n3.  **Application to the Facts:**\n    -   The $2018$ donor registration is the initial anatomical gift. It authorized four purposes: transplantation, therapy, research, and education.\n    -   The $2022$ advance health care directive is a later document from the same donor. It contains a clause that partially conflicts with the $2018$ gift. Specifically, it states a refusal for \"research or education.\"\n    -   According to premise (iii), this later document acts as an amendment to the earlier one. The $2022$ directive's refusal regarding \"research or education\" is inconsistent with the $2018$ authorization for those same purposes. Therefore, the later document's specific terms control, effectively revoking the authorization for research and education.\n    -   The problem explicitly states that the $2022$ directive \"made no mention of revoking transplantation or therapy uses.\" A partial amendment or revocation does not nullify the entire original gift unless it states so explicitly. The parts of the $2018$ gift that are not inconsistent with the $2022$ amendment remain in effect.\n    -   Therefore, the combined, legally effective intent of the donor is an anatomical gift for the purposes of \"transplantation and therapy\" only. The uses for \"research and education\" have been validly revoked. The OPO, having knowledge of both documents, is bound to respect this amended scope.\n\n**Evaluation of Options**\n\n*   **A. The $2018$ driver’s license donor registration controls in full; the organ procurement organization may use Alex’s tissues for research, education, transplantation, and therapy because the earlier, broader authorization cannot be narrowed by a later advance directive.**\n    This is **Incorrect**. This option directly contradicts premise (iii), which establishes that a later document from the donor amends or controls over an earlier, inconsistent one. The UAGA explicitly allows for amendments and revocations.\n\n*   **B. The $2022$ advance directive controls to the extent of its restriction; it validly amends the prior anatomical gift to bar research and education uses, while leaving transplantation and therapy uses authorized.**\n    This is **Correct**. This option accurately applies the principle from premise (iii). The later document ($2022$) amends the earlier one ($2018$) only to the extent of the specific inconsistency. It revokes the gift for research and education while leaving the unmentioned parts (transplantation and therapy) of the original gift intact. This respects the donor's final expressed intent.\n\n*   **C. Alex’s next of kin control because of the conflict; they may override both documents and decide whether to allow research or other uses.**\n    This is **Incorrect**. This option contradicts premise (ii), which prioritizes the \"donor’s documented intent over that of next of kin.\" The presence of a conflict between two of the donor's own documents does not automatically void the donor's authority and transfer it to relatives. The UAGA provides rules to resolve such conflicts to honor the donor's intent.\n\n*   **D. The conflict between the $2018$ and $2022$ documents voids both instruments; no anatomical gift is permitted for any purpose absent a court order.**\n    This is **Incorrect**. This conclusion is not supported by the premises. Legal interpretation, particularly under frameworks like the UAGA, seeks to give effect to intent rather than void it. Premise (iii) provides a clear mechanism for resolving inconsistency (the later document controls), which implies a resolution, not a total nullification of the donor's wish to make a gift. The conflict is partial, and thus the resolution is partial.", "answer": "$$\\boxed{B}$$", "id": "4501844"}, {"introduction": "When a person's tissues are transformed into a valuable commercial product without a clear agreement, complex legal questions arise that are not directly answered by statute. This scenario mirrors famous real-world legal battles and forces a consideration of common law doctrines. This exercise asks you to apply the property law doctrine of accession and the equitable principle of unjust enrichment to determine who owns a valuable new cell line and how its value should be fairly distributed among the original donor and the innovative researcher [@problem_id:4501838]. By integrating legal principles with a quantitative model of contribution, you will develop a nuanced argument for allocating property rights and monetary value in biotechnology.", "problem": "A donor, $D$, undergoes a clinically indicated biopsy. The hospital retains the excised tissue, and a researcher, $R$, later uses a sub-sample under $D$'s broad research consent, which is silent on commercialization and property allocation. $R$ derives an immortalized, edited cell line from $D$’s tissue using clustered regularly interspaced short palindromic repeats (CRISPR) edits and optimization steps, and obtains licensing interest from a biotechnology company. Assume a mixed common–civil law jurisdiction that recognizes the doctrine of accession and allows restitutionary recovery to prevent unjust enrichment.\n\nFundamental bases to use:\n- Property law definition: Title allocates the highest right to exclude over a thing; a residual claim can exist without title.\n- Doctrine of accession: When one party in good faith substantially transforms another’s property into a new species such that the identity is changed and the value added by labor/materials predominates, title to the new thing can vest in the improver, subject to compensation to the original owner measured by the contribution of the original material (e.g., value at the time of taking, or a proportionate share when the original thing’s distinctive attributes causally generate value).\n- Unjust enrichment: Restitution aims to reverse enrichment unjustly retained, measured by the value of the benefit to the recipient, which can be the market value of the contribution or a fair proportion of the net surplus where multiple causal inputs jointly produce the gain.\n- Intellectual Property (IP): Patents and know-how can attach to the modified cell line and are separate from title in the tangible biological material.\n\nFacts of valuation:\n- Market value of the licensed cell line: $V_f = \\$5{,}000{,}000$.\n- Documented research costs (labor, reagents, facilities): $C_R = \\$1{,}000{,}000$.\n- Fair market value of the raw tissue sample at time of derivation (comparable market for research-grade human tissue): $V_0 = \\$500$.\n- Evidence presented indicates that commercial differentiation of the final cell line is driven by approximately $5$ identifiable inputs of comparable causal weight: ($1$) donor’s unique genotype enabling the phenotype targeted by CRISPR edits; ($2$) immortalization protocol; ($3$) CRISPR edit design; ($4$) culture optimization; ($5$) regulatory and patent strategy. No bad faith is alleged.\n\nQuestion: Applying the doctrine of accession to determine title and integrating restitutionary principles to allocate value among causal contributors, which outcome and valuation split is most legally defensible on these facts?\n\nSelect one:\nA. Under accession, $R$ acquires title; $D$’s claim is limited to the raw material value $V_0$ (i.e., $\\$500$), with no proportionate share of added value.\nB. Under accession, $R$ acquires title; $D$ retains a restitutionary claim to a proportion of the net surplus attributable to $D$’s unique genotype. Given $5$ comparably weighted inputs, award $D$ $20\\%$ of the net surplus $S = V_f - C_R$, i.e., $\\$800{,}000$, and $R$ retains the remainder and title.\nC. $D$ and $R$ are co-owners of the cell line because $D$’s genetic information is unique; split the gross market value $V_f$ equally ($50/50$), awarding $\\$2{,}500{,}000$ to each.\nD. Under accession, $R$ acquires title; $D$ receives a fixed reasonable royalty of $5\\%$ on gross licensing revenue (i.e., $\\$250{,}000$), irrespective of costs or causal attribution.\nE. Human cell lines cannot be owned; therefore, neither party has title nor any monetary allocation, and any licensing value $V_f$ is legally non-cognizable.", "solution": "The problem statement is evaluated for validity prior to attempting a solution.\n\n**Step 1: Extract Givens**\n- **Parties:** A donor, $D$, and a researcher, $R$.\n- **Initial Material:** Excised tissue from $D$.\n- **Consent:** Broad research consent, silent on commercialization and property.\n- **Transformation:** $R$ creates an immortalized, edited cell line using CRISPR edits and optimization.\n- **Commercialization:** $R$ obtains licensing interest from a biotechnology company.\n- **Jurisdiction & Principles:** A mixed common–civil law jurisdiction recognizing:\n    - **Property Law:** Title allocates the highest right to exclude; a residual claim can exist without title.\n    - **Doctrine of Accession:** When one party in good faith substantially transforms another’s property into a new species such that identity is changed and value added predominates, title to the new thing can vest in the improver, subject to compensation to the original owner (measured by initial value or a proportionate share based on causal contribution).\n    - **Unjust Enrichment:** Restitution can be awarded, measured by the benefit to the recipient (market value of contribution or a fair proportion of net surplus).\n    - **Intellectual Property (IP):** Patents and know-how are distinct from title in the tangible material.\n- **Valuation Data:**\n    - Final market value of the cell line: $V_f = \\$5,000,000$.\n    - Documented research costs: $C_R = \\$1,000,000$.\n    - Fair market value of raw tissue: $V_0 = \\$500$.\n- **Causal Attribution:**\n    - $5$ identifiable inputs of comparable causal weight are established: ($1$) $D$’s unique genotype; ($2$) immortalization protocol; ($3$) CRISPR edit design; ($4$) culture optimization; ($5$) regulatory and patent strategy.\n- **State of Mind:** No bad faith is alleged.\n- **Question:** Determine the most legally defensible outcome for title and value allocation by applying the given doctrines.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is a well-constructed hypothetical scenario in the field of medical law and bioethics.\n- **Scientifically Grounded:** The underlying scientific context—biopsy, cell line derivation, CRISPR editing, and commercialization—is factually sound and represents a realistic area of modern biotechnology.\n- **Well-Posed:** The problem provides a clear set of legal principles (accession, unjust enrichment), specific quantitative data ($V_f, C_R, V_0$), and a structured model for causal attribution ($5$ comparable inputs). This allows for a determinate, logical solution.\n- **Objective:** The language is neutral and precise, avoiding subjective or biased statements. It presents the causal attribution as \"evidence presented,\" framing it as a factual premise for the legal analysis.\n\n**Step 3: Verdict and Action**\nThe problem is valid. The analysis will proceed.\n\n**Derivation of Solution**\n\nThe problem requires a two-part analysis: first, determination of title using the doctrine of accession, and second, allocation of value using principles of unjust enrichment.\n\n**Part 1: Determination of Title via Accession**\nThe doctrine of accession allows an improver to gain title to a transformed object if certain conditions are met. We assess these conditions:\n1.  **Good Faith:** The problem explicitly states, \"No bad faith is alleged.\" This condition is satisfied.\n2.  **Substantial Transformation into a New Species:** $R$ transformed a raw tissue sample into an \"immortalized, edited cell line.\" This is a fundamental change in character, function, and identity. The original tissue is perishable and has limited biological function ex vivo, whereas the cell line is immortal and has been genetically engineered for a specific purpose. This constitutes a transformation into a new species of chattel. This condition is satisfied.\n3.  **Predominance of Added Value:** The initial value of the property was $V_0 = \\$500$. The final product has a market value of $V_f = \\$5,000,000$. The value added by the researcher's labor, ingenuity, and materials (with costs of $C_R = \\$1,000,000$) vastly exceeds the value of the original material. The ratio of final to initial value is $\\$5,000,000 / \\$500 = 10,000$. The predominance of added value is indisputable. This condition is satisfied.\n\nSince all conditions for accession are met, title to the newly created cell line vests in the improver, the researcher $R$.\n\n**Part 2: Allocation of Value via Unjust Enrichment**\nAlthough $R$ gains title, the doctrine of accession requires compensation to the original owner, $D$. The problem directs us to integrate restitutionary principles to prevent unjust enrichment. The measure of recovery can be a \"fair proportion of the net surplus where multiple causal inputs jointly produce the gain.\"\n\n1.  **Calculate Net Surplus ($S$):** The net surplus is the final market value less the costs incurred to create that value.\n    $$S = V_f - C_R = \\$5,000,000 - \\$1,000,000 = \\$4,000,000$$\n\n2.  **Determine $D$'s Proportionate Share:** The problem specifies that the value is driven by $5$ identifiable inputs of \"comparable causal weight.\" One of these inputs is \"$D$’s unique genotype.\" The other four inputs are attributable to the researcher $R$'s efforts (protocol, design, optimization, strategy). Since the inputs are of comparable weight, each accounts for $1/5$ of the causal contribution to the surplus.\n    \n    $D$'s contribution is $1$ out of $5$ inputs. Therefore, $D$'s fair proportion of the net surplus is:\n    $$\\text{Share}_D = \\frac{1}{5} = 20\\%$$\n\n3.  **Calculate $D$'s Restitutionary Award:** $D$'s compensation is this proportionate share applied to the net surplus.\n    $$\\text{Award}_D = \\text{Share}_D \\times S = 0.20 \\times \\$4,000,000 = \\$800,000$$\n\nThis approach is consistent with the provided principles. It compensates $D$ far beyond the nominal value of the raw tissue ($V_0 = \\$500$) because the unique properties of that tissue (\"distinctive attributes\") are a direct causal contributor to the final value, justifying a proportionate share.\n\nThe remainder of the net surplus is attributable to $R$'s contributions ($4$ out of $5$ inputs, or $80\\%$).\n$$\\text{Award}_R = (1 - \\text{Share}_D) \\times S = 0.80 \\times \\$4,000,000 = \\$3,200,000$$\n\nThe total value $V_f$ is thus allocated as: $\\$1,000,000$ to cover $R$'s costs, $\\$800,000$ to $D$ as a restitutionary award, and $\\$3,200,000$ to $R$ as the return on $R$'s contributions.\n$\\$1,000,000 + \\$800,000 + \\$3,200,000 = \\$5,000,000$.\n\n**Summary of Derived Outcome:**\n- **Title:** Vests in $R$.\n- **Value Allocation:** $D$ is awarded $\\$800,000$. $R$ retains the remaining value after costs are covered.\n\n**Option-by-Option Analysis**\n\n**A. Under accession, $R$ acquires title; $D$’s claim is limited to the raw material value $V_0$ (i.e., $\\$500$), with no proportionate share of added value.**\n- **Analysis:** This option correctly identifies that $R$ acquires title under accession. However, it incorrectly limits $D$'s compensation to the initial value of the raw material, $V_0$. This contradicts the provided principle that allows for a \"proportionate share when the original thing’s distinctive attributes causally generate value,\" a condition explicitly met by the fact of $D$'s \"unique genotype\" being a key input.\n- **Verdict:** Incorrect.\n\n**B. Under accession, $R$ acquires title; $D$ retains a restitutionary claim to a proportion of the net surplus attributable to $D$’s unique genotype. Given $5$ comparably weighted inputs, award $D$ $20\\%$ of the net surplus $S = V_f - C_R$, i.e., $\\$800{,}000$, and $R$ retains the remainder and title.**\n- **Analysis:** This option aligns perfectly with the derived solution. It correctly states that $R$ acquires title. It correctly applies the principle of unjust enrichment to award $D$ a proportion of the net surplus ($S = V_f - C_R$). The proportion ($1/5$ or $20\\%$) is correctly derived from the causal attribution evidence ($5$ comparable inputs), and the final calculation ($20\\%$ of $\\$4,000,000$ is $\\$800,000$) is arithmetically correct.\n- **Verdict:** Correct.\n\n**C. $D$ and $R$ are co-owners of the cell line because $D$’s genetic information is unique; split the gross market value $V_f$ equally ($50/50$), awarding $\\$2{,}500{,}000$ to each.**\n- **Analysis:** This option is incorrect on two grounds. First, it proposes co-ownership, which is contrary to the doctrine of accession where title vests entirely in the good-faith improver. Second, the $50/50$ split of gross value is arbitrary and ignores both the documented research costs ($C_R$) and the specific causal attribution model ($1$ part $D$ to $4$ parts $R$), which does not support an equal split.\n- **Verdict:** Incorrect.\n\n**D. Under accession, $R$ acquires title; $D$ receives a fixed reasonable royalty of $5\\%$ on gross licensing revenue (i.e., $\\$250{,}000$), irrespective of costs or causal attribution.**\n- **Analysis:** This option correctly identifies $R$ as the title holder. However, the compensation mechanism is flawed. It uses a fixed royalty on gross revenue, which is inconsistent with the problem's direction to use a restitutionary approach based on a \"fair proportion of the net surplus.\" Furthermore, the claim that it is \"irrespective of ... causal attribution\" directly contradicts the instruction to use the $5$-input model. The amount calculated, $\\$250,000$, does not follow from the problem's framework.\n- **Verdict:** Incorrect.\n\n**E. Human cell lines cannot be owned; therefore, neither party has title nor any monetary allocation, and any licensing value $V_f$ is legally non-cognizable.**\n- **Analysis:** This option attempts to invalidate the problem's core premise. The question explicitly asks for an outcome *applying the doctrine of accession*, which is a property law doctrine concerning the vesting of title. To argue that the object cannot be owned is to reject the problem's instructions, not to solve it. Within the universe of the problem, the cell line is treated as property to which title can attach.\n- **Verdict:** Incorrect.", "answer": "$$\\boxed{B}$$", "id": "4501838"}, {"introduction": "In the era of large-scale genomics, property and privacy interests in genetic information are often managed through the lens of risk, not traditional ownership. Biobanks that share data for research must balance the immense public good of scientific discovery against the potential harm of re-identifying individual donors. This problem provides a hands-on application of how a fundamental concept from probability theory—expected value—can be used to create a quantitative risk budget for data release policies [@problem_id:4501836]. By calculating the maximum permissible dataset size under a given risk threshold, you will see how abstract ethical commitments to donor protection are operationalized into concrete, defensible governance rules.", "problem": "A university biobank holds human tissue and associated genetic variant data. The biobank claims custodial control over biospecimens, while recognizing donors’ continuing interests grounded in property-like claims and privacy. To respect those interests and to comply with de-identification standards such as the “very small” risk criterion under the Health Insurance Portability and Accountability Act (HIPAA), the biobank adopts a release policy that sets a quantitative “risk budget” for re-identification.\n\nConsider a dataset constructed for external release that includes data from $n$ distinct individuals. For each individual $i \\in \\{1,\\dots,n\\}$, let $X_{i}$ be an indicator random variable that equals $1$ if that individual is re-identified by an adversary after the release and equals $0$ otherwise. Assume that the ex ante probability of re-identification for each individual is identical and equal to $q$, that is, $\\mathbb{P}(X_{i}=1)=q$ for all $i$, and that $q$ is “small” in the sense common to expert risk determinations in data privacy. The biobank’s policy requires that the expected number of re-identifications in any single release does not exceed a fixed risk budget $\\tau>0$.\n\n1. Starting from the definition of expectation and without assuming independence, derive a general expression for $\\mathbb{E}\\!\\left[\\sum_{i=1}^{n} X_{i}\\right]$ in terms of $n$ and $q$. Then, using the policy constraint that the expected number of re-identifications must not exceed $\\tau$, solve for the maximal allowable dataset size $n_{\\max}$ as a function of $q$ and $\\tau$.\n\n2. Suppose expert assessment for a proposed genomics-only release yields a per-individual re-identification probability of $q=3.7\\times 10^{-5}$, and the biobank’s governance board adopts a risk budget of $\\tau=0.20$ expected re-identifications per release. Compute the corresponding $n_{\\max}$. Round your answer to four significant figures.\n\nIn addition to your derivation, briefly explain how the choice of $\\tau$ operationalizes property-rights-based concerns over human tissue and genetic information in setting data release policies, including how varying $\\tau$ affects $n_{\\max}$ and the balance between research utility and donor protection. Your final reported result must be the value of $n_{\\max}$ requested in part 2.", "solution": "We ground the analysis in two foundational elements: (a) the definition of expected value in probability theory and the linearity of expectation, and (b) the regulatory practice of constraining releases by a quantitative risk budget that represents a policy choice about acceptable expected harms.\n\n1. Let $X_{i}$ be the Bernoulli indicator of re-identification for individual $i$ with $\\mathbb{P}(X_{i}=1)=q$ and $\\mathbb{P}(X_{i}=0)=1-q$. The total number of re-identifications in the released dataset is\n$$\nS \\equiv \\sum_{i=1}^{n} X_{i}.\n$$\nBy the definition of expectation and the linearity of expectation,\n$$\n\\mathbb{E}[S] \\;=\\; \\mathbb{E}\\!\\left[\\sum_{i=1}^{n} X_{i}\\right] \\;=\\; \\sum_{i=1}^{n} \\mathbb{E}[X_{i}].\n$$\nEach $X_{i}$ is a Bernoulli random variable with mean $\\mathbb{E}[X_{i}]=1\\cdot q+0\\cdot (1-q)=q$. Therefore,\n$$\n\\mathbb{E}[S] \\;=\\; \\sum_{i=1}^{n} q \\;=\\; n q.\n$$\nThis derivation does not require independence; linearity of expectation holds without independence.\n\nThe biobank’s policy imposes the constraint that the expected number of re-identifications per release does not exceed the risk budget $\\tau$, that is,\n$$\n\\mathbb{E}[S] \\;\\leq\\; \\tau.\n$$\nSubstituting the expression for $\\mathbb{E}[S]$ yields\n$$\nn q \\;\\leq\\; \\tau.\n$$\nSolving for the maximal allowable dataset size as a real-valued bound gives\n$$\nn_{\\max} \\;=\\; \\frac{\\tau}{q}.\n$$\n\n2. With $q=3.7\\times 10^{-5}$ and $\\tau=0.20$, we compute\n$$\nn_{\\max} \\;=\\; \\frac{\\tau}{q} \\;=\\; \\frac{0.20}{3.7\\times 10^{-5}} \\;=\\; \\frac{0.20}{0.000037}.\n$$\nCarrying out the division,\n$$\nn_{\\max} \\;=\\; \\frac{2.0\\times 10^{-1}}{3.7\\times 10^{-5}} \\;=\\; \\left(\\frac{2.0}{3.7}\\right)\\times 10^{4} \\;=\\; 0.540540\\ldots \\times 10^{4} \\;=\\; 5405.405\\ldots.\n$$\nRounded to four significant figures, this is\n$$\n5405.\n$$\n\nPolicy discussion. The choice of $\\tau$ encodes a normative judgment about acceptable expected harms consistent with property-rights-based concerns over human tissue and genetic information. A smaller $\\tau$ reflects a more protective stance toward donors’ residual interests and control over identifiability, thereby reducing $n_{\\max}$ according to $n_{\\max}=\\tau/q$ and limiting the scale of releases or necessitating stronger technical and governance safeguards to lower $q$. Conversely, a larger $\\tau$ relaxes constraints, increasing $n_{\\max}$ and potentially enhancing research utility but at the cost of greater expected re-identification risk. Thus, $\\tau$ directly operationalizes the balance between research benefits and the protection of donor interests grounded in property and privacy norms, while $q$ captures technical risk conditioned by data features and mitigations. Governance bodies can adjust either parameter—tighten $\\tau$ or reduce $q$ via stronger de-identification and access controls—to align releases with ethical and legal commitments.", "answer": "$$\\boxed{5405}$$", "id": "4501836"}]}